Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
445 dni temu
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
700 dni temu
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
727 dni temu
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
799 dni temu
Positive Trend In Asian Markets
Equity markets in Asia closed on a positive note on Tuesday amidst growing hopes of more stimulus measures and expectations from the rate review by the Peoples Bank of China due on Wednesday.
RTTNews
|
5g 15 minut temu
RBA Vigilant To Upside Risks To Inflation, Minutes Show
The Reserve Bank of Australia remained vigilant to upside risks to inflation and the board affirmed that the policy would need to be sufficiently restrictive until inflation moves sustainably towards the target, the minutes of the policy board meeting held on November 4 and 5 showed Tuesday.
RTTNews
|
7g 36 minut temu
Antipodean Currencies Rise As Asian Markets Trade Mostly Higher
Antipodean currencies such as the Australian and the New Zealand dollars strengthened against their major currencies in the Asian session on Tuesday, as traders picked up some stocks at a bargain after the recent weakness in the markets amid concerns about the outlook for interest rates. Strong gains in mining and energy stocks also boosted the markets amid climbing commodity prices.
RTTNews
|
8g 4 minut temu
Super Micro Stock Surges After Hiring New Auditor; Plans To Avoid Delisting
Shares of Super Micro Computer Inc. surged around 40 percent in the extended trading on The Nasdaq Stock Market after the troubled server maker announced that it has hired a new auditor and filed a compliance plan with the stock exchange, with a view to avoiding its delisting. The plan was submitted to support its request for an extension of time to regain compliance with the Nasdaq...
RTTNews
|
8g 17 minut temu
